Updated:
Lotus Biosciences Ventures
Lotus Biosciences Ventures is a venture capital based in Hong Kong; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
Lotus Biosciences Ventures
Lotus Biosciences Ventures is a private equity firm based in Hong Kong SAR, China. It is a privately held entity.
General information
Firm type
Venture Capital
Location
Region
Asia
Country
Hong Kong
City
Hong Kong
Corporate office
Hong Kong
Sector focus
Frequently asked questions
What is Lotus Biosciences Ventures' investment strategy?
Lotus Biosciences Ventures targets early-stage life sciences companies, primarily at seed and Series A stages. The firm focuses on biotechnology, medical devices, and agricultural technology startups with defensible intellectual property. Investments center on companies based in or connected to Asian research institutions, with a goal of commercializing innovations globally.
In which geographic regions does Lotus Biosciences Ventures invest?
The firm invests primarily in companies across Greater China and Asia, leveraging Hong Kong's position as a financial hub. It seeks portfolio companies that can benefit from access to both Asian research talent and international regulatory and commercial pathways.
Does Lotus Biosciences Ventures focus on therapeutics or platforms?
Lotus Biosciences evaluates both therapeutic-focused biotechs and platform technology companies. Its portfolio interests span precision medicine, synthetic biology for agriculture, and digital health infrastructure, with an emphasis on innovations that address unmet needs in Asian and global markets.
How does the firm source its deal flow?
The firm sources opportunities through Hong Kong's scientific research community, university spinouts, and regional biotech incubators. Deal flow is enhanced by relationships with technology transfer offices at major Asian research universities and clinical research networks across the region.
Does Lotus Biosciences Ventures accept co-investors?
Lotus Biosciences has engaged with regional family offices and corporate strategic partners in healthcare and nutrition for co-investment opportunities. The firm's structure accommodates syndicated rounds with other specialist life sciences investors active in Asia-Pacific.
What is the firm's approach to portfolio company exits?
Exits are pursued through strategic acquisitions by global pharmaceutical and agribusiness companies, as well as public listings. Hong Kong Exchange's pre-revenue biotech listing chapter, adopted in 2018, provides a relevant exit pathway for portfolio companies meeting listing criteria.
Who makes investment decisions at Lotus Biosciences Ventures?
Specific named principals and investment committee composition are not publicly disclosed in available corporate filings. The firm's investment decisions are made by its Hong Kong-based team, which combines scientific domain expertise with venture capital experience focused on the life sciences sector.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: